8-K: Collegium Pharmaceutical Enters Agreement with Hikma for Authorized Generic Versions of Nucynta Products

Collegium Pharmaceutical has granted Hikma Pharmaceuticals exclusive rights to market authorized generic versions of its Nucynta IR and ER products in the United States.

Summary

• Collegium Pharmaceutical has entered into an agreement with Hikma Pharmaceuticals for the marketing of authorized generic versions of Nucynta IR and Nucynta ER in the United States.
• Hikma will have the exclusive right to market these authorized generic products.
• The launch of the authorized generics is planned 30 days before the loss of exclusivity for each product, or earlier under certain conditions.
• Collegium will supply Hikma with the products at Collegium's manufacturing cost.
• Hikma will pay Collegium a percentage of net profits, starting in the mid-80% range, which will decrease as more third-party generics enter the market.
• The agreement has an initial term of five years with automatic one-year renewals unless terminated.
• Hikma is restricted from marketing its own generic versions of Nucynta IR or ER while marketing the authorized generics.
• Hikma can terminate the agreement to launch its own generic version with one year's notice, but only after the first anniversary of the first authorized generic launch.

Sentiment

Score: 7

Explanation: The agreement is a positive development for Collegium, providing a continued revenue stream for its Nucynta products. However, the decreasing profit share and the risk of Hikma launching its own generic version temper the overall positive sentiment.

Positives

• The agreement provides Collegium with a revenue stream from its Nucynta products even after the loss of exclusivity.
• The profit share starting in the mid-80% range is favorable for Collegium.
• The exclusive marketing rights granted to Hikma should help maximize sales of the authorized generics.
• The agreement ensures Collegium will supply the product at its manufacturing cost, securing a consistent supply chain.
• The initial five-year term with automatic renewals provides long-term stability.

Negatives

• The profit share percentage will decrease as more third-party generics enter the market.
• Hikma has the option to terminate the agreement after one year to launch its own generic version, which could reduce Collegium's revenue.

Risks

• The entry of third-party generics could significantly reduce Collegium's profit share.
• Hikma could terminate the agreement after one year to launch its own generic version, impacting Collegium's revenue.
• There is a risk of material breach by either party, which could lead to termination of the agreement.
• Bankruptcy or insolvency of either party could also lead to termination of the agreement.

Future Outlook

The agreement is expected to provide Collegium with a continued revenue stream from its Nucynta products, even after the loss of exclusivity, although the profit share will decrease with increased generic competition. The agreement has an initial term of five years with automatic one-year renewals.

Management Comments

• The agreement was signed by Colleen Tupper, Executive Vice President and Chief Financial Officer of Collegium Pharmaceutical.

Industry Context

This agreement is a common strategy in the pharmaceutical industry to manage the loss of exclusivity for branded drugs. By partnering with a generic manufacturer, Collegium can maintain some revenue from its Nucynta products while also competing with other generic versions.

Comparison to Industry Standards

• Authorized generic agreements are a common practice in the pharmaceutical industry, with companies like Teva and Mylan frequently engaging in similar deals.
• The profit-sharing arrangement, starting in the mid-80% range, is generally favorable compared to typical generic agreements, which often have lower profit margins for the original manufacturer.
• The five-year term with automatic renewals is also standard for these types of agreements, providing a degree of long-term stability.
• The restriction on Hikma launching its own generic version while marketing the authorized generic is a common clause to protect the original manufacturer's revenue stream.

Stakeholder Impact

• Shareholders may view this agreement positively as it provides a continued revenue stream for Collegium.
• Employees may see this as a positive development for the company's financial stability.
• Customers will have access to generic versions of Nucynta products through Hikma.
• Suppliers will continue to provide materials for the manufacturing of Nucynta products.
• Creditors may view this agreement as a positive sign of Collegium's financial health.

Next Steps

• Hikma will launch the authorized generic versions of Nucynta IR and ER.
• Collegium will supply Hikma with the Nucynta AG Products.
• The AG Agreement will be filed as an exhibit to the Companys Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2024.

Key Dates

Keywords

Authorized Generic, Nucynta IR, Nucynta ER, Hikma Pharmaceuticals, Pharmaceutical Agreement, Generic Drugs, Profit Share, Exclusivity, Manufacturing Cost